ClinicalTrials.gg
RecruitingNCT07810777Updated Oct 28, 2026

PRA-216 Atopic Dermatitis Safety and Efficacy Study

A Phase 2 interventional study of Active PRA-216 and Placebo in Atopic Dermatitis (AD), sponsored by Prana Therapies Inc. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Prana Therapies Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Dermatitis, Atopic with a site in Australia — 12 open to participants now, 27 under way, 7 of them phase 3. Dermatitis, Atopic · Australia.

Planned enrollment
95th of 105
39 · median 226
Started
2026
with 5 others
Phase 2
40 of 110
3 open now
Primary completion
2027-09
later than 14 of 26 live
Registered
109th of 110
by date

Among the 110 studies in Dermatitis, Atopic with a site in Australia, this one is the 95th largest by planned enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 14 of the 26 other live ones, and was the 109th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

12 of the 110 studies in Dermatitis, Atopic with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Dermatitis, Atopic with a site in Australia, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)

Read the detailed description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy response of PRA-216 in patients with moderate to severe Atopic Dermatitis (AD). Eligible participants will be those with AD who are inadequately controlled by topical corticosteroids (TCS) or had adverse reaction or contraindication to the medication.

This study will enroll approximately 39 participants at multiple study sites who will be randomized 2:1 to receive either PRA-216 or placebo subcutaneous injections four times throughout the study period.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

Keywords

  • Inflammatory response
  • pharmacokinetics
  • pharmacodynamics
  • immunogenicity
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be in good health with no significant medical history
  • Willing and able to attend all study visits, comply with study requirements.
  • Able and willing to provide written
  • Documented AD diagnosis prior to enrollment.
  • History of inadequate response to topical medications for AD

Exclusion criteria

Exclusion Criteria:

  • Evidence of skin condition or disease other than AD
  • Any physical or psychological condition that prohibits study completion
  • Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent
  • History of severe allergic reactions or
  • Receipt of antibody therapy within 4 months or 5 half-lives
  • Other agent(s) within 30 days or 5 half-lives
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (estimated)

Study arms

  • Active comparator
    Active PRA-216

    Participants with moderate to severe AD will be randomized to receive PRA-216

    Drug: Active PRA-216

  • Placebo comparator
    Placebo

    Participants with moderate to severe AD will be randomized to receive placebo

    Drug: Placebo

Interventions

  • DrugActive PRA-216

    biologic

  • DrugPlacebo

    matching placebo for PRA-216

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of PRA-216 in patients with moderate to severe atopic dermatitis (AD)

    Time frame: Up to 28 weeks

Secondary outcomes

  1. Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD

    Mean percent change from baseline in Eczema Area and Severity Index (EASI). EASI is a score that will grade atopic dermatitis, with a higher number indicating more severe disease. A score of 0 indicates clear skin, and a score of 72 is severe disease.

    Time frame: Up to 24 weeks

  2. Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD: EASI-75

    Percentage of patients achieving EASI-75. EASI-75 indicates a 75% improvement in severity and spread of skin lesions compared to baseline.

    Time frame: Up to 24 weeks

  3. Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD: EASI-90

    Percentage of patients achieving EASI-90. EASI-90 indicates a 90% improvement in severity and spread of skin lesions compared to baseline.

    Time frame: Up to 24 weeks

  4. Pharmacokinetics of PRA-216: Tmax in patients with AD

    Time to maximum concentration of drug in plasma

    Time frame: Up to 28 weeks

  5. Pharmacokinetics of PRA-216: AUC in patients with AD

    Area under the curve

    Time frame: Up to 28 weeks

  6. Pharmacokinetics of PRA-216: Cmax in patients with AD

    Maximum concentration of PRA-216 in plasma

    Time frame: Up to 28 weeks

  7. Immunogenicity of PRA-216: ADA in patients with AD

    Incidence of anti-drug antibody following drug administration

    Time frame: Up to 24 weeks

07

Study locations

6 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2027 → Sep 2027 and completion Oct 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 9, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Sep 30, 2027was Jun 2027
CompletionEst.
May 16, 2028was Oct 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
1 site added. 8 sites changed recruiting status (6 now recruiting, 2 now not yet recruiting)
Show 8 sites
  • Emeritus Sydney · Botany, Australiano status→Recruiting
  • Cornerstone Centre for Clinical Research · Coorparoo, Australiano status→Recruiting
  • Emeritus Melbourne · Camberwell, Australiano status→Not yet recruiting
  • Momentum Sunshine · Melbourne, Australiano status→Not yet recruiting
  • Optimal Clinical Trials (North) · Auckland, New Zealandno status→Recruiting
  • Aotearoa Clinical Trials · Auckland, New Zealandno status→Recruiting
  • Momentum Christchurch · Christchurch, New Zealandno status→Recruiting
  • Clinical Trials New Zealand · Hamilton, New Zealandno status→Recruiting
Show site
  • Aperio Clinical Research · Liverpool, Australia
Oct 28, 2026
Start date
Sep 1, 2026→Sep 17, 2026 (actual)
Oct 28, 2026
Primary completion
Jun 30, 2027→Sep 30, 2027
Oct 28, 2026
Study completion
Oct 1, 2027→May 16, 2028
Oct 28, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedDocumented AD diagnosis prior for at least 6 months prior to enrollment.
Oct 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Emeritus Melbourne · Camberwell, AustraliaContact r•••@emeritusresearch.com · •••6166→r•••@emeritusresearch.com · •••6166Contact person changed (no phone or email listed)
  • Momentum Christchurch · Christchurch, New ZealandContact •••1976→•••1979
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    1 site added. 8 sites changed recruiting status (6 now recruiting, 2 now not yet recruiting)
    Show 8 sites
    • Emeritus Sydney · Botany, Australiano status→Recruiting
    • Cornerstone Centre for Clinical Research · Coorparoo, Australiano status→Recruiting
    • Emeritus Melbourne · Camberwell, Australiano status→Not yet recruiting
    • Momentum Sunshine · Melbourne, Australiano status→Not yet recruiting
    • Optimal Clinical Trials (North) · Auckland, New Zealandno status→Recruiting
    • Aotearoa Clinical Trials · Auckland, New Zealandno status→Recruiting
    • Momentum Christchurch · Christchurch, New Zealandno status→Recruiting
    • Clinical Trials New Zealand · Hamilton, New Zealandno status→Recruiting
    Show site
    • Aperio Clinical Research · Liverpool, Australia
    Start date Sep 1, 2026→Sep 17, 2026 (now actual)
    Primary completion Jun 30, 2027→Sep 30, 2027
    Study completion Oct 1, 2027→May 16, 2028
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedDocumented AD diagnosis prior for at least 6 months prior to enrollment.
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Emeritus Melbourne · Camberwell, AustraliaContact r•••@emeritusresearch.com · •••6166→r•••@emeritusresearch.com · •••6166Contact person changed (no phone or email listed)
    • Momentum Christchurch · Christchurch, New ZealandContact •••1976→•••1979
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07810777
Lead sponsor
Prana Therapies Inc
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Sep 17, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
May 16, 2028 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion